NASDAQ:GALT - Galectin Therapeutics Stock Price, Price Target & More

$3.16 -0.29 (-8.41 %)
(As of 04/25/2018 06:30 AM ET)
Previous Close$3.45
Today's Range$3.14 - $3.47
52-Week Range$1.28 - $6.74
Volume278,700 shs
Average Volume649,099 shs
Market Capitalization$129.62 million
P/E RatioN/A
Dividend YieldN/A
Beta2.53

About Galectin Therapeutics (NASDAQ:GALT)

Galectin Therapeutics logoGalectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.

Receive GALT News and Ratings via Email

Sign-up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GALT
CUSIPN/A
Phone678-620-3186

Debt

Debt-to-Equity RatioN/A
Current Ratio1.29%
Quick Ratio1.29%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.22) per share
Price / Book-14.36

Profitability

EPS (Most Recent Fiscal Year)($0.49)
Net Income$-16,230,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-188.34%

Miscellaneous

Employees7
Outstanding Shares37,570,000

How to Become a New Pot Stock Millionaire

Galectin Therapeutics (NASDAQ:GALT) Frequently Asked Questions

What is Galectin Therapeutics' stock symbol?

Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc. (NASDAQ:GALT) posted its quarterly earnings data on Thursday, March, 29th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.04. View Galectin Therapeutics' Earnings History.

When is Galectin Therapeutics' next earnings date?

Galectin Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, May, 21st 2018. View Earnings Estimates for Galectin Therapeutics.

What price target have analysts set for GALT?

3 brokers have issued twelve-month price objectives for Galectin Therapeutics' stock. Their predictions range from $5.00 to $10.00. On average, they anticipate Galectin Therapeutics' stock price to reach $7.6667 in the next year. View Analyst Ratings for Galectin Therapeutics.

Are investors shorting Galectin Therapeutics?

Galectin Therapeutics saw a increase in short interest in April. As of April 13th, there was short interest totalling 2,510,306 shares, an increase of 49.7% from the March 30th total of 1,676,645 shares. Based on an average daily trading volume, of 609,378 shares, the days-to-cover ratio is presently 4.1 days. Currently, 8.3% of the company's stock are short sold.

Who are some of Galectin Therapeutics' key competitors?

Who are Galectin Therapeutics' key executives?

Galectin Therapeutics' management team includes the folowing people:
  • Dr. Peter G. Traber, CEO, Pres & Chief Medical Officer (Age 63)
  • Mr. Jack W. Callicutt CPA, Chief Financial Officer (Age 51)
  • Dr. Harold H. Shlevin Ph.D., COO & Corp. Sec. (Age 68)
  • Robert Tritt, Gen. Counsel
  • Dr. Eliezer Zomer Ph.D., VP of Discovery Research & Product Devel. (Age 71)

Has Galectin Therapeutics been receiving favorable news coverage?

Media coverage about GALT stock has trended somewhat positive recently, Accern reports. The research firm identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Galectin Therapeutics earned a media sentiment score of 0.12 on Accern's scale. They also assigned news stories about the company an impact score of 47.61 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Galectin Therapeutics?

Shares of GALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Galectin Therapeutics' stock price today?

One share of GALT stock can currently be purchased for approximately $3.16.

How big of a company is Galectin Therapeutics?

Galectin Therapeutics has a market capitalization of $129.62 million. The company earns $-16,230,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. Galectin Therapeutics employs 7 workers across the globe.

How can I contact Galectin Therapeutics?

Galectin Therapeutics' mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company can be reached via phone at 678-620-3186 or via email at [email protected]


MarketBeat Community Rating for Galectin Therapeutics (GALT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  189 (Vote Outperform)
Underperform Votes:  146 (Vote Underperform)
Total Votes:  335
MarketBeat's community ratings are surveys of what our community members think about Galectin Therapeutics and other stocks. Vote "Outperform" if you believe GALT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GALT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Galectin Therapeutics (NASDAQ:GALT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Galectin Therapeutics in the last 12 months. Their average twelve-month price target is $7.6667, suggesting that the stock has a possible upside of 142.62%. The high price target for GALT is $10.00 and the low price target for GALT is $5.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.752.752.75
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.6667$6.25$6.25$4.6250
Price Target Upside: 142.62% upside42.69% upside42.69% upside84.26% upside

Galectin Therapeutics (NASDAQ:GALT) Consensus Price Target History

Price Target History for Galectin Therapeutics (NASDAQ:GALT)

Galectin Therapeutics (NASDAQ:GALT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/4/2018Roth CapitalBoost Price TargetBuy$3.00 -> $8.00MediumView Rating Details
12/7/2017HC WainwrightReiterated RatingBuy$6.00 -> $10.00HighView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$5.00N/AView Rating Details
4/3/2017FBR & CoReiterated RatingMarket Perform$2.00MediumView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Galectin Therapeutics (NASDAQ:GALT) Earnings History and Estimates Chart

Earnings by Quarter for Galectin Therapeutics (NASDAQ:GALT)

Galectin Therapeutics (NASDAQ:GALT) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.48 EPS
Next Year EPS Consensus Estimate: $-0.69 EPS

Galectin Therapeutics (NASDAQ GALT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/21/2018        
3/29/2018Q4 2017($0.11)($0.0730)ViewN/AView Earnings Details
11/7/2017Q3 2017($0.15)($0.13)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.15)($0.14)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.16)($0.15)ViewN/AView Earnings Details
3/28/2017Q4 2016($0.17)($0.13)ViewN/AView Earnings Details
11/8/2016Q3 2016($0.22)($0.19)ViewN/AView Earnings Details
8/9/2016Q2($0.24)($0.20)ViewN/AView Earnings Details
5/10/2016Q1($0.17)($0.24)ViewN/AView Earnings Details
3/15/2016Q415($0.22)($0.19)ViewListenView Earnings Details
11/9/2015Q3($0.20)($0.26)ViewN/AView Earnings Details
8/10/2015Q2($0.23)($0.21)ViewN/AView Earnings Details
5/11/2015Q115($0.20)($0.22)ViewN/AView Earnings Details
3/18/2015Q4 2014($0.17)ViewN/AView Earnings Details
11/10/2014Q314($0.27)($0.17)ViewN/AView Earnings Details
8/7/2014Q214($0.21)($0.17)ViewN/AView Earnings Details
5/13/2014Q114($0.20)($0.27)ViewN/AView Earnings Details
3/21/2014($0.18)($0.15)ViewN/AView Earnings Details
11/12/2013Q3($0.18)($0.22)ViewN/AView Earnings Details
8/14/2013Q213($0.19)($0.18)ViewN/AView Earnings Details
5/10/2013Q1 2013($0.18)($0.22)ViewN/AView Earnings Details
3/29/2013Q4 2012($0.20)($0.17)ViewN/AView Earnings Details
11/9/2012Q312($0.18)($0.19)ViewN/AView Earnings Details
8/10/2012Q2 2012($0.15)($0.19)ViewN/AView Earnings Details
5/11/2012Q1 2012($0.21)($0.17)ViewN/AView Earnings Details
3/30/2012Q4 2011($0.18)($0.29)ViewN/AView Earnings Details
11/10/2011Q3 2011($0.24)($0.19)ViewN/AView Earnings Details
8/12/2011Q2 2011($0.18)($0.34)ViewN/AView Earnings Details
5/13/2011Q1 2011($0.18)($0.24)ViewN/AView Earnings Details
3/15/2011Q4 2010($0.12)ViewN/AView Earnings Details
11/12/2010Q3 2010($0.12)($0.20)ViewN/AView Earnings Details
8/13/2010Q2 2010($0.28)ViewN/AView Earnings Details
5/12/2010Q1 2010($0.34)ViewN/AView Earnings Details
3/12/2010Q4 2009($0.13)ViewN/AView Earnings Details
11/13/2009Q3 2009($0.24)ViewN/AView Earnings Details
8/14/2009Q2 2009($0.40)ViewN/AView Earnings Details
5/15/2009Q1 2009($0.36)ViewN/AView Earnings Details
3/30/2009Q4 2008($0.17)ViewN/AView Earnings Details
11/7/2008Q3 2008$0.03ViewN/AView Earnings Details
8/8/2008Q2 2008($0.06)ViewN/AView Earnings Details
5/15/2008Q1 2008($0.21)ViewN/AView Earnings Details
3/28/2008Q4 2007($0.12)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Galectin Therapeutics (NASDAQ:GALT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Galectin Therapeutics (NASDAQ GALT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 45.20%
Institutional Ownership Percentage: 9.70%
Insider Trading History for Galectin Therapeutics (NASDAQ:GALT)
Institutional Ownership by Quarter for Galectin Therapeutics (NASDAQ:GALT)

Galectin Therapeutics (NASDAQ GALT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2018Theodore Daniel ZucconiDirectorSell4,000$3.58$14,320.005,083View SEC Filing  
4/4/2018Jack W CallicuttCFOSell3,349$5.00$16,745.004,609View SEC Filing  
2/1/2018Kevin D FreemanDirectorBuy2,000$4.10$8,200.0022,043View SEC Filing  
1/26/2018Fund L.P. 10XMajor ShareholderSell244,444$5.43$1,327,330.92View SEC Filing  
1/25/2018James C CzirrDirectorSell205,144$5.45$1,118,034.80View SEC Filing  
12/8/2017Marc RubinDirectorBuy7,000$1.85$12,950.0055,581View SEC Filing  
5/23/2017Theodore Daniel ZucconiDirectorBuy1,000$2.27$2,270.001,083View SEC Filing  
1/5/2016Arthur GreenbergDirectorBuy1,666$1.72$2,865.52109,445View SEC Filing  
8/12/2015Peter G TraberCEOBuy2,000$2.00$4,000.00View SEC Filing  
6/1/2015Kevin D FreemanDirectorBuy2,083$2.70$5,624.10View SEC Filing  
6/1/2015Peter G TraberCEOBuy4,000$2.53$10,120.00View SEC Filing  
8/19/2014Arthur GreenbergDirectorBuy1,000$4.56$4,560.00View SEC Filing  
8/15/2014Kevin D FreemanDirectorBuy1,000$4.70$4,700.00View SEC Filing  
8/14/2014Jack W CallicuttCFOBuy1,000$4.55$4,550.00View SEC Filing  
8/14/2014Peter G TraberCEOBuy4,000$4.46$17,840.00View SEC Filing  
8/13/2014Peter G TraberCEOBuy1,000$4.42$4,420.00View SEC Filing  
4/11/2014Steven PrelackDirectorSell6,000$11.84$71,040.00View SEC Filing  
1/13/2014James C CzirrChairmanSell100,000$14.84$1,484,000.00View SEC Filing  
12/4/2013Marc RubinDirectorBuy3,000$8.69$26,070.00View SEC Filing  
11/19/2013Arthur GreenbergDirectorBuy2,000$6.55$13,100.00View SEC Filing  
11/19/2013Peter G TraberCEOBuy1,000$5.53$5,530.00View SEC Filing  
11/18/2013Peter G TraberCEOBuy1,000$5.80$5,800.00View SEC Filing  
11/15/2013James C CzirrChairmanBuy1,000$6.90$6,900.00View SEC Filing  
6/3/2013John F MauldinDirectorBuy1,176$4.21$4,950.96View SEC Filing  
5/28/2013Kevin D FreemanDirectorBuy1,000$4.21$4,210.00View SEC Filing  
10/12/2012Peter G TraberCEOBuy2,500$2.11$5,275.00View SEC Filing  
10/9/2012Peter G TraberCEOBuy2,500$2.00$5,000.00View SEC Filing  
10/8/2012Peter G TraberCEOBuy5,000$2.07$10,350.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Galectin Therapeutics (NASDAQ GALT) News Headlines

Source:
DateHeadline
Galectin Therapeutics (GALT) Cut to Strong Sell at ValuEngineGalectin Therapeutics (GALT) Cut to Strong Sell at ValuEngine
www.americanbankingnews.com - April 25 at 12:58 AM
Blog Exposure - Adamas Pharma Announced Final Results from EASE LID 2 Study Evaluating GOCOVRI in Parkinson’s Disease Patients with DyskinesiaBlog Exposure - Adamas Pharma Announced Final Results from EASE LID 2 Study Evaluating GOCOVRI in Parkinson’s Disease Patients with Dyskinesia
finance.yahoo.com - April 23 at 9:00 AM
Galectin Therapeutics Inc (GALT) Director Sells $14,320.00 in StockGalectin Therapeutics Inc (GALT) Director Sells $14,320.00 in Stock
www.americanbankingnews.com - April 18 at 8:14 PM
Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018
finance.yahoo.com - April 18 at 8:46 AM
Galectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces andGalectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and
www.nasdaq.com - April 16 at 9:15 AM
Galectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effects of GR-MD-02 in Patients With NASH CirrhosisGalectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effects of GR-MD-02 in Patients With NASH Cirrhosis
finance.yahoo.com - April 16 at 9:15 AM
Galectin Therapeutics (GALT) Downgraded by ValuEngineGalectin Therapeutics (GALT) Downgraded by ValuEngine
www.americanbankingnews.com - April 14 at 1:59 PM
ValuEngine Lowers Galectin Therapeutics (GALT) to SellValuEngine Lowers Galectin Therapeutics (GALT) to Sell
www.americanbankingnews.com - April 13 at 11:10 PM
-$0.13 EPS Expected for Galectin Therapeutics Inc (GALT) This Quarter-$0.13 EPS Expected for Galectin Therapeutics Inc (GALT) This Quarter
www.americanbankingnews.com - April 12 at 3:18 AM
Galectin Therapeutics (GALT) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowGalectin Therapeutics (GALT) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 10 at 5:22 PM
Galectin Therapeutics Inc (GALT) CFO Sells $16,745.00 in StockGalectin Therapeutics Inc (GALT) CFO Sells $16,745.00 in Stock
www.americanbankingnews.com - April 6 at 7:33 PM
Galectin Therapeutics (GALT) to Present Late-Breaker Oral Presentation at The International Liver CongressGalectin Therapeutics (GALT) to Present Late-Breaker Oral Presentation at The International Liver Congress
www.streetinsider.com - April 4 at 4:36 PM
Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018
finance.yahoo.com - April 4 at 4:35 PM
ValuEngine Downgrades Galectin Therapeutics (GALT) to SellValuEngine Downgrades Galectin Therapeutics (GALT) to Sell
www.americanbankingnews.com - April 3 at 3:37 PM
Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences ConferenceGalectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - April 2 at 5:28 PM
These Biotech Stocks Have a Strong Green Close on FridayThese Biotech Stocks Have a Strong Green Close on Friday
finance.yahoo.com - March 30 at 8:41 AM
Galectin Therapeutics (GALT) Issues  Earnings Results, Beats Expectations By $0.04 EPSGalectin Therapeutics (GALT) Issues Earnings Results, Beats Expectations By $0.04 EPS
www.americanbankingnews.com - March 29 at 2:21 PM
Galectin Therapeutics Reports 2017 Financial Results and Provides Business UpdateGalectin Therapeutics Reports 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 29 at 8:27 AM
Pre-Market Earnings Report for March 29, 2018 : STZ, SAIC, WOR, LNN, ANGO, FINL, MOV, TITN, ALDX, GALT, ALTPre-Market Earnings Report for March 29, 2018 : STZ, SAIC, WOR, LNN, ANGO, FINL, MOV, TITN, ALDX, GALT, ALT
www.nasdaq.com - March 28 at 5:19 PM
Galectin Therapeutics (GALT) Upgraded by ValuEngine to HoldGalectin Therapeutics (GALT) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - March 25 at 11:21 AM
Galectin Therapeutics (GALT) to Release Earnings on ThursdayGalectin Therapeutics (GALT) to Release Earnings on Thursday
www.americanbankingnews.com - March 22 at 1:14 AM
Galectin Therapeutics Inc (GALT) Receives Average Rating of "Buy" from AnalystsGalectin Therapeutics Inc (GALT) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 18 at 11:56 AM
Galectin Therapeutics (GALT) Presents At 30th Annual ROTH Conference - SlideshowGalectin Therapeutics (GALT) Presents At 30th Annual ROTH Conference - Slideshow
seekingalpha.com - March 13 at 5:39 PM
Galectin Therapeutics to Present at Two International Conferences in MarchGalectin Therapeutics to Present at Two International Conferences in March
finance.yahoo.com - March 9 at 9:57 AM
Galectin Therapeutics to Present at 2nd Annual H.C. Wainwright NASH Investor ConferenceGalectin Therapeutics to Present at 2nd Annual H.C. Wainwright NASH Investor Conference
finance.yahoo.com - March 8 at 9:34 AM
Galectin Therapeutics Announces Record Date and Annual Stockholders Meeting Date for 2018Galectin Therapeutics Announces Record Date and Annual Stockholders Meeting Date for 2018
finance.yahoo.com - March 5 at 5:24 PM
Galectin Therapeutics to Present at 30th Annual ROTH ConferenceGalectin Therapeutics to Present at 30th Annual ROTH Conference
finance.yahoo.com - February 28 at 5:29 PM
NASH Pathogenesis: Better Understanding And A Look At Galectin - Seeking AlphaNASH Pathogenesis: Better Understanding And A Look At Galectin - Seeking Alpha
seekingalpha.com - February 22 at 8:24 AM
Galectin Therapeutics Inc (GALT) Given Average Rating of "Buy" by BrokeragesGalectin Therapeutics Inc (GALT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 21 at 2:11 PM
-$0.11 EPS Expected for Galectin Therapeutics Inc (GALT) This Quarter-$0.11 EPS Expected for Galectin Therapeutics Inc (GALT) This Quarter
www.americanbankingnews.com - February 20 at 5:14 AM
Update On Galectin Therapeutics Potential Entry Into Cancer Market - Seeking AlphaUpdate On Galectin Therapeutics' Potential Entry Into Cancer Market - Seeking Alpha
seekingalpha.com - February 16 at 8:13 AM
Galectin Therapeutics (GALT) Presents At BIO CEO & Investor Conference - SlideshowGalectin Therapeutics (GALT) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 14 at 3:31 PM
Galectin Therapeutics (GALT) Stock Rating Upgraded by Zacks Investment ResearchGalectin Therapeutics (GALT) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 7 at 12:06 AM
Galectin Therapeutics to Present at BIO CEO & Investor ConferenceGalectin Therapeutics to Present at BIO CEO & Investor Conference
feeds.benzinga.com - February 6 at 9:27 AM
Zacks: Brokerages Anticipate Galectin Therapeutics Inc (GALT) Will Post Earnings of -$0.11 Per ShareZacks: Brokerages Anticipate Galectin Therapeutics Inc (GALT) Will Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - February 3 at 5:12 AM
Galectin Therapeutics (GALT) Rating Lowered to Sell at Zacks Investment ResearchGalectin Therapeutics (GALT) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 31 at 12:54 AM
Galectin Therapeutics Inc (GALT) Major Shareholder Fund L.P. 10X Sells 244,444 SharesGalectin Therapeutics Inc (GALT) Major Shareholder Fund L.P. 10X Sells 244,444 Shares
www.americanbankingnews.com - January 30 at 12:14 AM
Galectin Therapeutics Inc (GALT) Director Sells $1,118,034.80 in StockGalectin Therapeutics Inc (GALT) Director Sells $1,118,034.80 in Stock
www.americanbankingnews.com - January 30 at 12:14 AM
Galectin Therapeutics: Lackluster Trial Results, Bad Credit Line Somehow Jump Stock 300% - Seeking AlphaGalectin Therapeutics: Lackluster Trial Results, Bad Credit Line Somehow Jump Stock 300% - Seeking Alpha
seekingalpha.com - January 29 at 3:29 PM
Is Galectin Therapeutics Inc’s (NASDAQ:GALT) CEO Pay Fair?Is Galectin Therapeutics Inc’s (NASDAQ:GALT) CEO Pay Fair?
finance.yahoo.com - January 29 at 7:16 AM
Galectin Therapeutics Inc (GALT) Receives Average Recommendation of "Hold" from BrokeragesGalectin Therapeutics Inc (GALT) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 27 at 11:56 AM
Galectin Therapeutics (GALT) Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy - StreetInsider.comGalectin Therapeutics (GALT) Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy - StreetInsider.com
www.streetinsider.com - January 27 at 7:11 AM
Galectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development ProgramsGalectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development Programs
finance.yahoo.com - January 25 at 3:28 PM
Galectin Therapeutics Is On To Something Big - Seeking AlphaGalectin Therapeutics Is On To Something Big - Seeking Alpha
seekingalpha.com - January 7 at 5:34 PM
Galectin Therapeutics (GALT) Price Target Increased to $8.00 by Analysts at Roth CapitalGalectin Therapeutics (GALT) Price Target Increased to $8.00 by Analysts at Roth Capital
www.americanbankingnews.com - January 4 at 9:48 AM
Are Options Traders Betting on a Big Move in Galectin Therapeutics (GALT) Stock?Are Options Traders Betting on a Big Move in Galectin Therapeutics (GALT) Stock?
finance.yahoo.com - January 4 at 9:34 AM
Galectin Therapeutics Inc (GALT) Receives Average Rating of "Hold" from AnalystsGalectin Therapeutics Inc (GALT) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 2 at 12:44 PM
Galectin Therapeutics (GALT) Downgraded by ValuEngine to "Strong Sell"Galectin Therapeutics (GALT) Downgraded by ValuEngine to "Strong Sell"
www.americanbankingnews.com - January 2 at 12:50 AM
Galectin Therapeutics Inc (GALT) Short Interest Up 87.7% in DecemberGalectin Therapeutics Inc (GALT) Short Interest Up 87.7% in December
www.americanbankingnews.com - December 31 at 4:22 AM
Head-To-Head Analysis: Galectin Therapeutics (GALT) versus Its RivalsHead-To-Head Analysis: Galectin Therapeutics (GALT) versus Its Rivals
www.americanbankingnews.com - December 21 at 3:28 PM

SEC Filings

Galectin Therapeutics (NASDAQ:GALT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Galectin Therapeutics (NASDAQ:GALT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Galectin Therapeutics (NASDAQ GALT) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.